News & Updates
Filter by Specialty:

Negative mood worsens dyspnoea in COPD
A negative affective state can aggravate dyspnoea in patients with chronic obstructive pulmonary disease (COPD), a study has shown. This suggests that reducing the likelihood of negative mood or improving the mood can help in managing morbidities associated with dyspnoea in COPD.
Negative mood worsens dyspnoea in COPD
10 Mar 2024
Severe COVID-19 rare in PrEP-treated SARDs patients
Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024
Pulse vs nonpulse corticosteroid: Which is better against IPF?
Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) who received a pulse dose of corticosteroids do not appear to have longer survival than those who received conventional nonpulse dose of corticosteroids, results of a study have shown.
Pulse vs nonpulse corticosteroid: Which is better against IPF?
07 Mar 2024
High CRP level tied to earlier death in ILD
Increased levels of serum C-reactive protein (CRP) may contribute to shorter survival in patients with idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), or systemic sclerosis (SSc)-associated ILD at 5 years.
High CRP level tied to earlier death in ILD
07 Mar 2024
Needle-free epinephrine an alternative for anaphylaxis?
In a study presented at AAAAI 2024, epinephrine in preservative-free, nasal powder formulations demonstrated superior stability and comparable plasma exposure to the EpiPen® autoinjector, thus providing a less-invasive treatment option for severe allergic reactions including anaphylaxis.
Needle-free epinephrine an alternative for anaphylaxis?
07 Mar 2024
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.